Skip to main content
. 2020 Sep 22;2020:8851525. doi: 10.1155/2020/8851525

Figure 4.

Figure 4

Cisplatin reduces expressions of Cx26 and Cx43 in SV. (a) The distribution of Cx26 (green) in BCs by immunofluorescence staining. The moderate-to-strong Cx26 signal is visible in the cell cytoplasm of BCs in the control, while the weak-to-moderate Cx26 signal is seen in cisplatin-treated mice. Nuclei were stained with DAPI (blue). Scale bars, 100 μm. (b, c). The distribution of Cx43 (green) in the MCs (b) and BCs (c) by immunofluorescence staining. After the treatment of cisplatin, the weak-to-moderate Cx43 signal was found in the SV. A strong signal for Cx43 was found in some MCs in cisplatin-treated mice. Nuclei were stained with DAPI (blue). Scale bars, 100 μm. (d) Western blot analysis of the cell lysates of SV treated with cisplatin. β-Actin was used as a loading control. (e) Densitometric quantification of the mean (SD) ratio of Cx43 and Cx26 expressed as mean ± SD (n = 3). (f) qRT-PCR shows mRNA for Cx43 and Cx26 in the SV (n = 3). (g) The ultrastructure of SV analyzed by TEM. The number of anchoring connections at the basal layer is reduced in cisplatin-treated mice. Arrows point to anchoring connections. Scale bars, 10 μm. BC: basal cells; SL: spiral ligament; Con: 0.9% physiological saline; Cis: cisplatin. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.